Healthcare and Medical

home | healthcare and medical | company profile

£265.00
Alerts
Change Currency EuroUSDGBP

Introgen Therapeutics Inc - Premium Company Profile (Datamonitor)

  • Market: Healthcare and Medical
  • Published Date: 22/04/2008
  • Report Title: Introgen Therapeutics Inc - Premium Company Profile
  • Table of Contents: View Table of Contents
  • Report Type: Company Profile
  • Country: Global
  • Number of Pages: 53
Introduction

Introgen Therapeutics (Introgen) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer. The company has been successful in developing a strong portfolio of pipeline candidates using its ‘Enabling Technologies’.

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


  • Highlights

    The company’s product candidates include includes five clinical-stage product candidates: ADVEXIN and INGN 241 in Phase III clinical trials for head and neck cancer; INGN 225, a therapeutic p53 vaccine, in Phase II clinical development for lung and breast cancer.

    The company's INGN 234, a topical formulation for oral cancer prevention and treatment of oral pre-malignancies, in Phase I clinical development; and INGN 401, a systemic nanoparticle tumor suppressor is in Phase II clinical trials for metastatic lung cancer.

    The company recognizes revenues in the form of contract research fees from other pharmaceutical/biotechnology companies, and grants from academic and government organizations. The company’s total revenues have slightly declined at a CAGR of 0.5% during 2002-2006, almost flat at $1.2 million.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company’s adjusted five year financial data along with key ratios and market capitalization
  • £265.00   Share Report
     
    Alerts  

    Purchase Information

    There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses Worldpay. Worldpay is part of The Royal Bank of Scotland Group, the 5th biggest banking group in the world. Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.

    Worldpay Logo
    Chancy Currency EUR USD GBP
    Customer Area
    English Italian Spanish French German Russian Chinese Arabic